Skip to content
DataLookout
Menu

NCT06101082

A Clinical Study Evaluating the Safety and Efficacy of Anti-HER2-CAR-T Cells Injection in Patients With Solid Tumors

StatusUnknown
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Mar 2024); last known: Recruiting
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Oct 25, 2023 to Jan 16, 2024
    • Site details revised
    v3
  3. Minor Study title shortened, about 7 wordsv2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Dose-limiting toxicity
Timeframe: 21 days within anti-HER2-CAR-T cell infusion

Secondary (1)

Objective response rate

Arms and interventions

Anti-HER2-CAR-T cell infusionExperimental

Anti-HER2-CAR-T cell is administered as a single intravenous infusion. Follow-up infusions are based on the investigator's decision.The dose group to be infusion was 1×10\^6 CAR-T cells/kg, 3×10\^6 CAR-T cells/kg, and 1×10\^7 CAR-T cells/kg based on the 3+3 dose escalation principle. The infusion dose refers to the number of CAR-positive cells.The patients will receive lymphocyte clearance therapy with cyclophosphamide and fludarabine before the infusion.

Biologicals: Intravenous infusion anti-HER2-CAR-T cell

Sites

1 site in 1 country

  • Phase I Clinical Trials Center Of The First Hospital of China Medical UniversityShenyang, Liaoning, China